Sarcoma & GIST
Conference Coverage
Lurbinectedin shows activity against relapsed Ewing’s
CHICAGO – The agent blocks DNA transcription and induces double-strand breaks leading to apoptosis; results warrant further exploration,...
Conference Coverage
Adjuvant chemotherapy benefits high-risk sarcoma patients
Chemotherapy halved the risk of disease progression and death for patients with low probability of 10-year overall survival.
Conference Coverage
Rapid drug alteration a bust in metastatic GIST
Short alternating cycles of sunitinib with regorafenib failed to reach active drug levels in patients with heavily pretreated disease.
Conference Coverage
ctDNA profiles pre- and posttreatment KIT mutations in GIST
CHICAGO – A broad spectrum KIT inhibitor should be a part of post-imatinib therapy for GIST, data from a phase 1 study suggest.
Conference Coverage
Novel TKI PLX9486 showed efficacy against KIT mutations in GIST
CHICAGO – Combined with another investigational tyrosine kinase inhibitor, the compound showed activity against a broad range of resistance...
Conference Coverage
Low response rate with trofosfamide for advanced STS in elderly
CHICAGO – Of 80 patients with previously untreated metastatic soft-tissue sarcomas, 2 had complete, durable responses to oral trofosfamide.
News
Trabectedin bests supportive care in advanced soft-tissue sarcomas
CHICAGO – The benefit of trabectedin vs. best supportive care was entirely in patients with leiomyosarcoma or liposarcoma.
Conference Coverage
DESMOPAZ: Pazopanib slows disease progression of desmoid tumors
Pazopanib elicited clinically meaningful responses in adults with progressive desmoid tumors according to RECIST 1.1 criteria, based on two...
Conference Coverage
Metastatic soft tissue sarcomas respond to anlotinib
Anlotinib was confirmed to be safe and effective for soft tissue sarcoma patients who have progressed after first-line chemotherapy, based on...
Conference Coverage
REGOBONE: Regorafenib shows efficacy in metastatic osteosarcoma
Regorafenib appears to be active in patients with metastatic osteosarcomas, based on results from REGOBONE a non-comparative phase 2, double-blind...
Conference Coverage
Sorafenib boosts PFS in desmoid tumor patients
Sorafenib was well tolerated with significantly improved progression-free survival in select patients with desmoid tumors, reported Mrinal M....